Stocktoria
uniQure N.V. QURE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-02-05
uniQure N.V. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $16.1M | $27.1M | $15.8M | $106.5M | $524.0M |
| R&D expense | $140.7M | $143.8M | $214.9M | $197.6M | $143.5M |
| SG&A expense | $65.5M | $52.7M | $74.6M | $55.1M | $56.3M |
| Operating income | -$185.3M | -$184.3M | -$282.9M | -$143.2M | $310.6M |
| Interest expense | — | — | $41.6M | $11.7M | $7.5M |
| Income tax | $5.6M | $2.4M | $1.9M | -$1.5M | $3.2M |
| Net income | -$199.0M | -$239.6M | -$308.5M | — | — |
| EPS (diluted) | $-3.46 | $-4.92 | $-6.47 | $-2.71 | $7.04 |
| Operating cash flow | -$178.0M | -$182.7M | -$145.9M | -$145.1M | $288.0M |
| Free cash flow | -$178.4M | -$186.1M | -$153.1M | -$162.7M | $270.5M |
| Cash & equivalents | $80.2M | $158.9M | $241.4M | $228.0M | $556.3M |
| Inventory | — | — | $12.0M | $6.9M | — |
| Total assets | $824.9M | $556.5M | $831.7M | $705.0M | $809.2M |
| Total liabilities | $626.0M | $563.3M | $624.0M | $229.0M | $213.4M |
| Shareholders' equity | $198.9M | -$6.8M | $207.7M | $476.0M | $595.8M |
Source: SEC EDGAR filings · CIK 0001590560 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.